Page 1 | Search Results | Blood Advances | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Tycel J. Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Ping Jiang, Peter Johnson

Blood Adv (2024) 8 (4): 867–877.

https://doi.org/10.1182/bloodadvances.2023010648

Published: 2024

Includes: Supplemental data

Journal Articles

Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort

Hervé Ghesquières, Fanny Cherblanc, Aurélien Belot, Sophie Micon, Krimo K. Bouabdallah, Cyril Esnault, Luc-Matthieu Fornecker, Katia Thokagevistk, Maxime Bonjour, Fontanet Bijou, Corinne Haioun, Nadine Morineau, Loïc Ysebaert, Gandhi Damaj, Benoit Tessoulin, Stéphanie Guidez, Franck Morschhauser, Catherine Thiéblemont, Adrien Chauchet, Rémy Gressin, Fabrice Jardin, Christophe Fruchart, Gaëlle Labouré, Ludovic Fouillet, Pauline Lionne-Huyghe, Antoine Bonnet, Laure Lebras, Sandy Amorim, Cécile Leyronnas, Gaelle Olivier, Romain Guieze, Roch Houot, Vincent Launay, Bernard Drénou, Olivier Fitoussi, Laurence Detourmignies, Julie Abraham, Carole Soussain, Florence Lachenal, Gian Matteo Pica, Patrick Fogarty, Pascale Cony-Makhoul, Adeline Bernier, Sandra Le Guyader-Peyrou, Alain Monnereau, Frédéric Boissard, Cédric Rossi, Vincent Camus

Blood Adv (2024) 8 (2): 296–308.

https://doi.org/10.1182/bloodadvances.2023010798

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Blood Adv (2023) 7 (22): 7141–7150.

https://doi.org/10.1182/bloodadvances.2023010298

Published: 2023

Includes: Supplemental data

Journal Articles

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

Blood Adv (2023) 7 (22): 6801–6811.

https://doi.org/10.1182/bloodadvances.2023010668

Published: 2023

Includes: Supplemental data

Journal Articles

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

Blood Adv (2023) 7 (21): 6589–6598.

https://doi.org/10.1182/bloodadvances.2023010624

Published: 2023

Includes: Supplemental data

Journal Articles

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

Blood Adv (2023) 7 (15): 3968–3977.

https://doi.org/10.1182/bloodadvances.2022008888

Published: 2023

Includes: Supplemental data

Journal Articles

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

Vincent Camus, Aurélien Belot, Lucie Oberic, David Sibon, Hervé Ghesquières, Catherine Thieblemont, Christophe Fruchart, Olivier Casasnovas, Jean-Marie Michot, Thierry Jo Molina, André Bosly, Clémentine Joubert, Corinne Haioun, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Olivier Fitoussi, Richard Delarue, Hervé Tilly

Blood Adv (2022) 6 (24): 6169–6179.

https://doi.org/10.1182/bloodadvances.2022007609

Published: 2022

Includes: Supplemental data

Journal Articles

A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma

Blood Adv (2022) 6 (23): 5995–6004.

https://doi.org/10.1182/bloodadvances.2021006923

Published: 2022

Includes: Supplemental data

Journal Articles

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

Blood Adv (2022) 6 (22): 5835–5843.

https://doi.org/10.1182/bloodadvances.2022008150

Published: 2022

Journal Articles

Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma

Alexis Cuffel, Vincent Allain, Lionel Faivre, Roberta Di Blasi, Florence Morin, Laetitia Vercellino, Mathieu F. Chevalier, Aude Desnoyer, Romain de Jorna, Isabelle Madelaine, Nathalie Parquet, Anne C. Brignier, Catherine Thieblemont, Jerome Larghero, Sophie Caillat-Zucman, Miryam Mebarki

Blood Adv (2022) 6 (15): 4657–4660.

https://doi.org/10.1182/bloodadvances.2022007057

Published: 2022

Includes: Supplemental data

Journal Articles

Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP

Sophie Bernard, Herve Ghesquieres, Rene-Olivier Casasnovas, Samuel Griolet, Maria Gomes da Silva, Pierre Feugier, Franck Morschhauser, Judith Trotman, Loic Renaud, Richard Greil, Alejandro Martín García-Sancho, Sebastian Grosicki, Koen van Eygen, Christiane Copie-Bergman, Corinne Haioun, Catherine Thieblemont

Blood Adv (2021) 5 (15): 2965–2968.

https://doi.org/10.1182/bloodadvances.2021004766

Published: 2021

Includes: Supplemental data

Journal Articles

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Ariela Noy, Sven de Vos, Morton Coleman, Peter Martin, Christopher R. Flowers, Catherine Thieblemont, Franck Morschhauser, Graham P. Collins, Shuo Ma, Shachar Peles, Stephen D. Smith, Jacqueline C. Barrientos, Elizabeth Chong, Shiquan Wu, Leo W.-K. Cheung, Kevin Kwei, Bernhard Hauns, Israel Arango-Hisijara, Robert Chen

Blood Adv (2020) 4 (22): 5773–5784.

https://doi.org/10.1182/bloodadvances.2020003121

Published: 2020

Includes: Supplemental data

Journal Articles

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Blood Adv (2020) 4 (22): 5607–5615.

https://doi.org/10.1182/bloodadvances.2020003001

Published: 2020

Includes: Supplemental data

NARROW

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma

Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only